febrile neutropenia
FDA Approves Nivestym, Second Biosimilar of Neupogen
The FDA approved Pfizer's Nivestym, a biosimilar of Neupogen for all eligible indications as the reference ...
JULY 23, 2018
FDA Approves Fulphila, First Biosimilar to Neulasta
Mylan's Fulphila is the first biosimilar to Neulasta to decrease the chance of infection as suggested by febrile ...
JUNE 4, 2018
Load more